Jefferies Financial Group Equities Analysts Raise Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) – Analysts at Jefferies Financial Group lifted their Q3 2022 earnings estimates for shares of Esperion Therapeutics in a report released on Tuesday, August 2nd. Jefferies Financial Group analyst M. Yee now forecasts that the biopharmaceutical company will post earnings per share of ($0.87) for the quarter, up from their prior forecast of ($0.92). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($3.72) per share. Jefferies Financial Group also issued estimates for Esperion Therapeutics’ Q4 2022 earnings at ($0.82) EPS, FY2022 earnings at ($3.66) EPS, Q1 2023 earnings at ($0.59) EPS, Q2 2023 earnings at ($0.57) EPS, Q3 2023 earnings at ($0.56) EPS, Q4 2023 earnings at ($0.53) EPS, FY2023 earnings at ($2.25) EPS and FY2024 earnings at $0.38 EPS.

Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.10). The business had revenue of $18.80 million for the quarter, compared to the consensus estimate of $18.62 million. The firm’s revenue was down 53.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.67) EPS.

Several other equities analysts have also weighed in on ESPR. Credit Suisse Group lowered shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their target price for the company from $7.00 to $6.00 in a report on Wednesday. Morgan Stanley lifted their target price on shares of Esperion Therapeutics from $5.00 to $7.00 and gave the company an “underweight” rating in a report on Friday, July 15th. Finally, JPMorgan Chase & Co. upgraded shares of Esperion Therapeutics from an “underweight” rating to a “neutral” rating and set a $6.00 target price on the stock in a report on Wednesday, May 4th. Four analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Esperion Therapeutics has a consensus rating of “Hold” and an average price target of $20.67.

Esperion Therapeutics Trading Up 3.0 %

NASDAQ:ESPR opened at $6.10 on Friday. The firm has a market capitalization of $384.34 million, a price-to-earnings ratio of -0.96 and a beta of 0.28. The firm’s fifty day simple moving average is $6.08 and its 200 day simple moving average is $5.28. Esperion Therapeutics has a twelve month low of $3.28 and a twelve month high of $15.05.

Insider Buying and Selling

In related news, insider Joanne M. Foody sold 3,901 shares of Esperion Therapeutics stock in a transaction on Tuesday, July 19th. The shares were sold at an average price of $6.55, for a total transaction of $25,551.55. Following the sale, the insider now owns 109,077 shares of the company’s stock, valued at approximately $714,454.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 8,905 shares of company stock valued at $50,693 in the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Pictet Asset Management SA increased its position in shares of Esperion Therapeutics by 45.3% in the 4th quarter. Pictet Asset Management SA now owns 191,547 shares of the biopharmaceutical company’s stock worth $958,000 after purchasing an additional 59,698 shares during the last quarter. National Bank of Canada FI bought a new stake in shares of Esperion Therapeutics during the 4th quarter valued at about $61,000. Deerfield Management Company L.P. Series C bought a new stake in shares of Esperion Therapeutics during the 4th quarter valued at about $25,000,000. Denali Advisors LLC bought a new stake in shares of Esperion Therapeutics during the 1st quarter valued at about $49,000. Finally, Ensign Peak Advisors Inc bought a new stake in shares of Esperion Therapeutics during the 4th quarter valued at about $666,000.

About Esperion Therapeutics

(Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Featured Articles

• Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
• MarketBeat: Week in Review 8/1 – 8/5
• How to Use High Beta Stocks to Maximize Your Investing Profits
• Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
• Why Apple Could Be At All-Time Highs By Year End
• Beyond Meat Is Not Beyond Hope, And It’s Cheap

Want More Great Investing Ideas?